Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

e the long-term safety of pirfenidone in patients with IPF. ITMN-191 (R7227): -- In November 2008, Roche, InterMune and Pharmasset, Inc. initiated the first all-oral combination study of direct anti-virals in the absence of interferon or ribavirin, known as the INFORM-1 study. That study has completed the first dose cohort. -- On January 12, 2009, InterMune announced top-line results from a 14-day, Phase 1b study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). - After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts in the study, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively. - Reductions in HCV RNA occurred rapidly and there was no evidence of viral rebound during ITMN-191 treatment in any cohort. - ITMN-191 was generally safe and well tolerated in the study. There were no serious adverse events or Grade 4 adverse events (AEs) during treatment with ITMN-191. AEs reported during study treatment (ITMN-191 or placebo) were predominantly mild to moderate in severity, typically consistent with the AE profile of standard of care (SOC), and none led to treatment discontinuation. Financial: -- On February 19, 2009, InterMune completed a follow-on public offering of 4,025,000 shares of common stock, including the underwriters' over-allotment, at an offer price of $16.35 per share. Net proceeds to InterMune were approximately $63.5 million after deduction of underwriting fees and other related expenses. -- The Medicines Company announced on February 25, 2009, that it had completed its tender offer for all of the outstanding shares of Targanta Therapeutics Co
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Underscores Morphotek,s Commitment to the Development of Farletuzumab ... Specialty Development and Manufacturing SolutionsEXTON, Pa. and BASEL, ... of Eisai Corporation of North America, and Lonza ... executed a manufacturing services agreement to support the ...
... and biotech,companies are drawing on Singapore,s integrated network ... productivity, leverage academic,insights and diversify risks. Located at ... is representative of key Asian ethnic groups, Singapore ... and develop new solutions for,Asia and beyond. , ...
... signed an agreement-in-principle to ensure the valorization and the operation ... the Faculty of veterinary medicine in St-Hyacinthe, Quebec, Canada, for ... ... Laval, Quebec (PRWEB) May 18, 2009 -- Universite de ...
Cached Biology Technology:Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 2Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 3Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat to ... declines of amphibians, bats, corals, bees and snakes. ... published in the prestigious journal Nature ... resistance to a deadly chytrid fungus implicated in ... is important because it is the basis of ...
(Date:7/9/2014)... 2014Biofuels derived from the oils produced by algae may ... achieve this goal, optimization of cost effective strategies for ... is needed. Sapphire Energy has developed an innovative solution ... cultivation systems, described in Industrial Biotechnology , a ... article is available on the Industrial Biotechnology ...
(Date:7/9/2014)... Genome Atlas (TCGA) Research Network have identified novel ... adenocarcinoma, the most common subtype of lung cancer. ... number of possible therapeutic targets for this disease ... with treatable mutations because many potent cancer drugs ... is jointly funded and managed by the National ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Controlling contamination in open algae ponds for biofuels 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... Hill, CA Bowman Design Group, an integrated marketing and ... marketing, is the first and only company in the ... the German exhibition and events industry association. Third party ... company met or exceeded goals set for nine criteria ...
... DIEGO At the Plenary Session of the American ... AAPS President Tony DeStefano, Ph. D. will present the ... the pharmaceutical sciences: AAPS Ligand Binding Assays ... Alison Joyce, B.S. (lead author); Sheldon Leung, Ph.D.; ...
... When determining the potential effects pesticides could pose ... Protection Agency, National Marine Fisheries Service (NMFS), and ... common scientific approach, says a new report from ... should use a risk assessment approach that addresses ...
Cached Biology News:Bowman Design Group is first US company awarded German FAMAB 'Sustainable Company' certification 2AAPS announces 2013 National Biotechnology Conference award winners 2Agencies should use common approach to evaluate risks pesticides pose to endangered species 2Agencies should use common approach to evaluate risks pesticides pose to endangered species 3
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... is from the C-terminal end of the mouse retinoic acid receptor beta ... to 448 of RAR*. The sequence of PEP-005 is (amino to ... P - S - S - V - E - N - ... P - L - L - Q (The N-terminal cysteine has ...
... use of small interfering RNA (siRNA) molecules ... interference (RNAi) pathway have generated tremendous interest ... siRNA for experimental use can be synthesized ... then transfected into the target cells in ...
... is an automated hybridization system for the ... both the hybridization and post hybridization washing ... single instrument can process up to 12 ... has multi-protocol software, enabling the user to ...
Biology Products: